BRAF and neoplasm: Targeting oncogenic BRAF makes melanoma more immunogenic and promotes a more favorable TME by normalizing tumor vasculature, enhancing melanoma antigen presentation, and inducing cytotoxic CD8+ cells infiltration [3, 4, 5, 6].